Sign in
Taking people in United StatesNo phase

Ear and sound nerve stimulation for gut symptoms in hypermobile Ehlers-Danlos syndrome

Tests nerve stimulation for gut symptoms in hypermobile Ehlers-Danlos syndrome.

Key facts

Who runs it
Medical College of Wisconsin
Where
Milwaukee, United StatesSee the site
Trial code
Registry title
Auricular Vagal Nerve Stimulation for Hypermobile Ehlers-Danlos Syndrome
Status
Recruiting
People taking part
90 people, planned
Started
5 Apr 2021
Expected to end
31 Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Percutaneous vagal nerve stimulation (pVNS) device
  • Acoustic vagal nerve stimulation (aVNS) treatment
Record updated
13 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children aged 10 to 18 with upper stomach or gut complaints. They must also have suspected hypermobile Ehlers-Danlos syndrome (hEDS), a related joint hypermobility disorder (HSD), or a problem with the nervous system that controls automatic body functions.

Age
10 to 18 years
Sex
All
Disease stage
Functional upper GI complaints (no damage or disease found to explain them). Also a clinical suspicion of hEDS or HSD with a Beighton score of at least 4/9, or a suspected problem with the automatic nervous system (ANS dysfunction). No other explanation for the symptoms.
Earlier treatment
Cannot join if a new drug that affects the brain or nerves was started in the 2 weeks before enrolment.
Biomarker or test result
Beighton score (a joint flexibility test) of at least 4/9 for the hEDS or HSD group.

Main reasons for not taking part

  • Complex medical problems, or a disease or medicine that could explain the symptoms
  • Other gut diseases, such as peptic ulcer, H.pylori gastritis, celiac disease, inflammatory bowel disease, allergic or metabolic disorders
  • Significant developmental delay
  • Pregnancy
  • Long-term alcohol or illegal drug use, or smoking

The registry criteria, word for word

Show all 32 criteriaShow less

Who can take part

  • Children aged 10-18 years old
  • Children with functional upper GI complaints and clinical suspicion for hEDS or HSD as well as a Beighton score of at least 4/9
  • Children with functional upper GI complaints and clinical suspicion for ANS dysfunction
  • De-identified data from our prior studies (IRB #689519 and IRB #1064187) of patients with functional GI disorders who do NOT meet criteria for hEDS will be used as a comparison group
  • Children who are English-speaking and lack other explanation for symptoms
  • Children willing to participate and consent to this study (for children, have a parent willing to participate)

Who cannot take part

  • Patients who are treated with a new drug affecting the central nervous system in the two weeks prior to enrollment will also be excluded
  • Chronic alcohol/illicit drug use and/or smoking
  • Exclusion Criteria for subjects undergoing pVNS therapy:
  • Exclusion Criteria for subjects undergoing aVNS therapy:
  • Patients with pacemakers, metal clips used in previous surgery or other device which are not compatible with MRI scanning
  • Medically complex children or those who take a medication or suffer from a disease that can explain symptoms will be excluded from participation in the study
  • Patients with findings of organic disease such as peptic ulcer disease, H.pylori gastritis, celiac disease, inflammatory bowel disease, allergic disorders, metabolic disorder or any other chronic condition or medication that may cause chronic GI symptoms will be excluded from the study
  • Severe dermatological condition or active infection of external or middle ear
  • Seizure disorder
  • Egg allergy or anticipated inability to complete a standardized egg meal
  • Bleeding disorder for the specific biopsies
  • Exclusion Criteria applying to all participants:
  • Adult subjects, children or their parents who have significant developmental delay (will be excluded due to difficulties in accurately completing the questionnaires and assessing symptoms)
  • Pregnancy (evaluating MD screens patients as they normally would during a clinic visit (by questioning) and would only perform urine pregnancy test if clinically indicated (absence of menstrual period or other symptoms concerning for pregnancy)
  • Implanted electrical device
  • Hearing impaired
  • Sight impaired without correction
  • Exclusion Criteria for subjects undergoing gastric motor function sub-study:
  • Claustrophobia or inability to lie still in the scanner
  • Orthodontic braces or permanent retainers
  • Patients who are unable to tolerate noise produced by the MRI
  • Exclusion Criteria for subjects undergoing HepGI Biobank specimen collection sub-study:
  • Recent antibiotic usage for fecal sample
  • Significant anemia or clinical status which will not allow safe blood draw required for blood collection
  • Refusal of blood collection or to provide DNA sample
  • Inability or unwillingness on the individual (or parent/legal guardian) to provide clinical or family history

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 10 and 18 years old?

Where in United States

  • Medical College of WisconsinMilwaukee, United StatesContact: Elaina Schueler, BATaking people

About the trial

What the trial wants to find out

Hypermobile Ehlers-Danlos Syndrome (hEDS) is a connective tissue disorder characterized by hyperextensible skin, joint hypermobility and additional connective tissue manifestations. For unclear reasons, hEDS is associated with many gastrointestinal (GI) and autonomic nervous system (ANS) complaints such as postural orthostatic tachycardia syndrome (POTS). This study will address the clinical relationship between hEDS/Hypermobile Spectrum Disorders and autonomic regulation and see if there is a benefit of two forms of non-invasive vagal nerve stimulation therapies to reduce GI symptoms in hEDS and POTS. The study will also investigate plausible effects of these nerve stimulation therapies on gastric function and autonomic signaling.

The 2 groups in the trial

  • Treatment Arm A (hEDS)Existing treatment, for comparison

    (n=60) patients who meet criteria for hEDS or Hypermobile Spectrum Disorder (HSD) will receive aVNS (acoustic vagal nerve stimulation) therapy via filtered vocal music sound therapy using the Safe and Sound protocol (randomized 1:1 to active vs sham music; double blind study design)

    Treatment: Acoustic vagal nerve stimulation (aVNS) treatment

  • Treatment Arm B (ANS Dysfunction)Treatment being tested

    (n=30) patients with concerns for ANS dysfunction (with or without hEDS) will receive auricular percutaneous vagal nerve stimulation (pVNS) therapy. Additional sub-study option: 15-20 subjects will undergo gastric MRI and (those who consent to it) will also participate in a biobank blood sample collection study.

    Treatment: Percutaneous vagal nerve stimulation (pVNS) device

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Hypermobile Ehlers-Danlos Syndrome: Efficacy of Non-invasive Vagal Nerve Stimulation and Effects on Brain-Gut Physiology
Plain-language title
Ear and sound nerve stimulation for gut symptoms in hypermobile Ehlers-Danlos syndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT05212129, who can take part
Record updated
13 February 2026